FDA Approves Automated Scanning System for ALK Gene Mutations | Lung Cancer Dispatch | Scoop.it

Three percent to 5% of non-small cell lung cancer (NSCLC) patients have a mutation in the ALK gene and may benefit from treatment with critozinib (Xalkori). In 2011, the FDA approved a test that samples NSCLC tissue and highlights ALK mutations with a glowing tag. Now, the FDA has approved an automated scanning system, GenASIs Scan & Analysis, for examining these tagged tissue samples. The automated system, produced by Applied Spectral Imaging, promises fast, reliable detection of ALK mutations in NSCLC.


Press Release: http://www.spectral-imaging.com/news-and-events/news?elq=666b179d69bb426e96e2bb8761261d25